On March 9, 2023, Apeiron Investment Group Ltd announced that it delivered a letter to Sensei Biotherapeutics, Inc nominating a slate of 3 qualified candidates, including Peter Miles Davies, Lorin Van Nuland, and Matthew N. Shenkman for election to the Company?s Board of Directors at the Company?s 2023 annual meeting of stockholders. In addition, Apeiron Investment believes that the nominees have the qualifications, experience and skill sets necessary to serve as directors of the Company, as evidenced by their biographies.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.62 USD | +8.72% | +3.18% | +134.10% |
May. 14 | Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target | MT |
May. 09 | Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+134.10% | 37.37M | |
+7.97% | 113B | |
+10.44% | 106B | |
+0.41% | 22.27B | |
-11.92% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-4.96% | 17.24B | |
+6.63% | 14.29B | |
+36.01% | 12.52B |
- Stock Market
- Equities
- SNSE Stock
- News Sensei Biotherapeutics, Inc.
- Apeiron Investment Nominates Candidates to the Board of Sensei Biotherapeutics